IN8bio Overview
Latest ROE for IN8bio: -101.66% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-101.66%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
IN8bio (INAB) currently reports a ROE of -101.66%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore IN8bio's ROE history and peer comparisons.
IN8bio's ROE of -101.66% is lower than the Healthcare sector average of 22.76%. That is roughly 546.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but IN8bio's current -101.66% should be judged against Healthcare norms (sector average: 22.76%) and against INAB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -101.66%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for IN8bio, and consider following INAB for alerts when major investors trade the stock.
IN8bio is classified in the Healthcare sector. On ROE, it currently shows -101.66% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INAB with unrelated industries.
